The following table provides reconciliation from U.S. GAAP Net income to non-GAAP Adjusted EBITDA (amounts in thousands): [["", "", "Fiscal Years Ended March 31,", ""], ["", "2019", "2018", "2017"], ["Net income (U.S. GAAP) (1)", "$206,587", "$254,127", "$47,157"], ["Non-GAAP adjustments:", "", "", ""], ["Income tax expense (benefit)", "(39,460)", "9,132", "4,294"], ["Interest expense, net", "19,204", "32,073", "39,731"], ["Depreciation and amortization", "52,628", "50,661", "38,151"], ["EBITDA (non-GAAP) (1)", "238,959", "345,993", "129,333"], ["Excluding the following items:", "", "", ""], ["Equity (income) loss from equity method investments", "3,304", "(76,192)", "(41,643)"], ["Acquisition (gain) loss", "\u2014", "(130,880)", "\u2014"], ["Change in value of TOKIN options", "\u2014", "\u2014", "(10,700)"], ["(Gain) loss on write down and disposal of long-lived assets", "1,660", "(992)", "10,671"], ["ERP integration costs/IT transition costs", "8,813", "80", "7,045"], ["Stock-based compensation", "12,866", "7,657", "4,720"], ["Restructuring charges (2)", "8,779", "14,843", "5,404"], ["R&D grant reimbursements and grant income", "(4,559)", "\u2014", "\u2014"], ["Legal expenses/fines related to antitrust class actions", "11,896", "16,636", "2,640"], ["Net foreign exchange (gain) loss", "(7,230)", "13,145", "(3,758)"], ["TOKIN investment-related expenses", "\u2014", "\u2014", "1,101"], ["Plant start-up costs (2)", "(927)", "929", "427"], ["Loss on early extinguishment of debt", "15,946", "486", "\u2014"], ["Adjusted EBITDA (non-GAAP) (1)", "$289,507", "$191,705", "$105,240"]]